NCT06990399Phase 3Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Study sponsor: Kodiak Sciences Inc · KOD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-04Estimated

Enrollment · participants600Estimated

Source updated2026-05-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-18 · 2 fields changed

Planned enrollment increased by 450 participants

− Before

~~150 participants (planned)~~

+ After

600 participants (planned)

Primary completion date changed

− Before

~~Feb 2026~~

+ After

Apr 2027

Check registry source